Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. J Health Econ. 2012;31:158–68.
Bobinac A, van Exel NJ, Rutten FF, Brouwer WB. Willingness to pay for a quality-adjusted life-year: the individual perspectivevhe. Value Health. 2010;13(8):1046–55.
Zhao FL, Yue M, Yang H, Wang T, Wu JH, Li SC. Willingness to pay per quality-adjusted life year: is one threshold enough for decision-making? results from a study in patients with chronic prostatitis. Med Care. 2011;49:267–72.
Martín-Fernández J, Polentinos-Castro E, del Cura-González I, Ariza-Cardiel G, Abraira V, Gil-LaCruz AI, et al. Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences. BMC Health Serv Res. 2014;14:287.
Mozaffari S, Nikfar S, Abdolghaffari AH, Abdollahi M. New biologic therapeutics for ulcerative colitis and Crohn’s disease. Expert Opin Biol Ther. 2014;14(5):583–600.
Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian MA, Henry D, et al. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. DARU. 2013;21:50.
Hashemi-Meshkini A, Keshavarz K, Gharibnaseri Z, Kheirandish M, Kebriaeezadeh A, Nikfar S, et al. Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer. Arch Med Sci. 2013;9(3):472–8.
Rezvanfar MA, Kebriaeezadeh A, Moein M, Nikfar S, Gharibnaseri Z, Abdollahi-Asl A. Cost analysis of childhood asthma in Iran: A cost evaluation based on referral center data for asthma and allergies. J Res Pharm Pract. 2013;2(4):162–8.
Gharibnaseri Z, Kebriaeezadeh A, Nikfar S, Zamani G, Abdollahiasl A. Cost-effectiveness of adding-on new antiepileptic drugs to conventional regimens in controlling intractable seizures in children. DARU. 2012;20:17.
Kebriaeezadeh A, Nassiri Koopaei N, Abdollahiasl A, Nikfar S, Mohamadi N. Trend analysis of the pharmaceutical market in Iran; 1997–2010; policy implications for developing countries: DARU 2013;21:52.
Abdollahiasl A, Nikfar S, Abdollahi M. Pharmaceutical market and health system in the Middle Eastern and Central Asian countries: Time for innovations and changes in policies and actions. Arch Med Sci. 2011;7(3):365–7.
Abdollahiasl A, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Cheraghali AM, Jaberidoost M, et al. A system dynamics model for national drug policy. DARU. 2014;22:34.
Abdollahiasl A, Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M. A model for developing a decision support system to simulate national drug policy indicators. Arch MED Sci. 2011;7(5):744–6.
Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health Policy Plan. 2013;28:692–704.
Nikfar S, Kebriaeezadeh A, Majdzadeh R, Abdollahi M. Monitoring of National Drug Policy (NDP) and its standardized indicators; conformity to decisions of the national drug selecting committee in Iran. BMC Int Health Hum Rights. 2005;5(1):5.
Salari P, Namazi HR, Abdollahi M, Khansari F, Nikfar S, Larijani B, et al. Code of ethics for the national pharmaceutical system: Codifying and compilation. J Res Med Sci. 2013;18(5):442–8.